{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '55', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'conduct this type of research, it is important to identify tumor-specific mutations that occur', 'across all genes in the tumor genome. Evaluation of molecular targets and signaling', 'pathways including angiogenesis- or and growth factor related signaling pathways related to', 'pembrolizumab and lenvatinib may also be explored. Thus, genome-wide approaches may be', 'used for this effort. Note that in order to understand tumor-specific mutations, it is necessary', 'to compare the tumor genome with the germline genome. Circulating tumor DNA and/or', 'RNA may also be evaluated from blood samples.', 'Tumor and blood RNA analyses', 'Both genome-wide and targeted messenger RNA (mRNA) expression profiling and', 'sequencing in tumor tissue and in blood may be performed to define gene signatures that', 'correlate to clinical response to treatment with pembrolizumab or other immunotherapies.', 'Pembrolizumab induces a response in tumors that likely reflects an inflamed/immune', 'phenotype. Specific immune-related gene sets (ie, those capturing interferon-gamma', 'transcriptional pathways) may be evaluated and new signatures may be identified. Individual', 'genes related to the immune system and growth factor signaling pathways (eg, VEGF and', 'FGF) may also be evaluated. MicroRNA profiling may also be pursued as well as exosomal', 'profiling.', 'Proteomics and immunohistochemistry (IHC) using blood or tumor', 'Tumor and blood samples from this study may undergo proteomic analyses (eg, PD-L1 IHC).', 'PD-L1 protein level in tumor sections, assessed by IHC, has been shown to correlate with', 'response to pembrolizumab in patients with NSCLC, and an in vitro diagnostic (IVD) device', 'has been developed for use with pembrolizumab in NSCLC. Preliminary data indicates that', 'this association may also be true in additional cancer types (ie, triple negative breast cancer,', 'head and neck, and gastric). Additional tumor or blood-derived proteins may also correlate', 'with response to pembrolizumab and lenvatinib combination therapy. Therefore, tumor tissue', 'may be subjected to proteomic analyses using a variety of platforms that could include but', 'are not limited to immunoassays and liquid chromatography/mass spectrometry. This', 'approach could identify novel protein biomarkers that could aid in patient selection for', 'pembrolizumab (MK-3475) and lenvatinib combination therapy.', 'Other blood-derived biomarkers', 'In addition to expression on the tumor tissue, PD-L1, circulating cytokines and angiogenic', 'factors, and other tumor derived proteins can be shed from tumor and released into the blood.', 'Assays such as enzyme-linked immunoassay (ELISA) measure such proteins in serum.', 'Correlation of expression with response to pembrolizumab and lenvatinib combination', 'therapy may identify new approaches for predictive biomarkers in blood, representing a', \"major advance from today's reliance on assessing tumor biomarkers. This research would\", 'serve to develop such assays for future clinical use.', 'Other molecular changes of interest include the subtype of T-cells in the tumor', 'microenvironment. The T-cell repertoire from tumor tissue and blood components may be', 'evaluated.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '56', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.2', 'Rationale for the Use of Comparator/Placebo', 'Based on the results of KEYNOTE-024, pembrolizumab monotherapy has become the SOC', 'for treating Stage IV NSCLC in patients with PD-L1 TPS >50% with no EGFR or ALK', 'genomic tumor aberrations. The study resulted in a significant PFS benefit for', 'pembrolizumab over the SOC at the time (platinum-doublet therapy), with an HR of', '0.50 (95% CI, 0.37-0.68; p<0.001; median PFS, 10.3 months [95% CI, 6.7 to not reached]', 'with pembrolizumab and 6.0 months [95% CI, 4.2-6.2 months] with platinum-doublet) as', 'well as an OS benefit with an HR of 0.60 (95% CI 0.41-0.89; p=0.005; median OS was not', 'reached in either treatment arm) [Reck, M., et al 2016]. The results from KEYNOTE-024', 'established pembrolizumab as 1L therapy for patients whose tumors have a TPS >50% and in', 'whom EGFR- or ALK-directed therapies are not indicated, and the regimen has received', 'regulatory approval for this use by the FDA and EMA. Additionally, based on results from', 'KEYNOTE-042, pembrolizumab monotherapy is considered one of the treatment options in', 'treating Stage IV NSCLC in patients with PD-L1 TPS 1% with no EGFR or ALK genomic', 'tumor aberrations. The study resulted in a significant os benefit for pembrolizumab over the', 'SOC at the time (platinum-doublet therapy), with an HR of 0.81 (95% CI, 0.71-0.93;', 'p=0.0018). Median OS was 16.7 months (95% CI, 13.9-19.7 months) with pembrolizumab', 'and 12.1 months (95% CI, 11.3-13.3 months) with platinum-doublet therapy [Lopes, G., et al', '2018].', 'The use of a lenvatinib matching placebo in combination with pembrolizumab will ensure the', \"objectivity of the local investigators' treatment decision and AE causality assessments, while\", 'still providing participants the SOC treatment.', '4.3', 'Justification for Dose', '4.3.1', 'Maximum Dose/Exposure for This Study', 'NOTE: As of Amendment 007-06, lenvatinib, matching placebo, and Second-course', 'treatment have been removed from the study. This section has been updated', 'accordingly.', 'The maximum dose/exposure of pembrolizumab allowed in this study is 200 mg Q3W up to', '35 cycles (approximately 2 years) for the Initial Treatment Phase.', '4.3.2', 'Rationale for Dose Interval and Study Design', '4.3.2.1', 'Lenvatinib Dosing', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable, but has been left unchanged for', 'reference.', 'The dosing regimen of lenvatinib was selected based on the results of the Phase 1b portion of', 'Phase 1b/2 Study 111/KEYNOTE-146, of which the primary endpoint was to determine the', 'MTD and RP2D for lenvatinib in combination with pembrolizumab 200 mg Q3W. Thirteen', 'participants (lenvatinib 24 mg/day + pembrolizumab 200 mg IV Q3W: n=3; lenvatinib 20', 'mg/day + pembrolizumab 200 mg: n=10) were enrolled into the Phase 1b portion of the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']\n\n###\n\n", "completion": "END"}